

ALKALOID AD SKOPJE STATUTORY STAND-ALONE FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS' REPORT FOR THE YEAR ENDED DECEMBER 31, 2021

(In thousands of Denar)

CONTENTS	Page
INDEPENDENT AUDITORS' REPORT	1
STAND-ALONE STATEMENT OF FINANCIAL POSITION	3
STAND-ALONE STATEMENT OF PROFIT OR LOSS	4
STAND-ALONE STATEMENT OF COMPREHENSIVE INCOME	5
STAND-ALONE STATEMENT OF CHANGES IN EQUITY	6
STAND-ALONE STATEMENT OF CASH FLOWS	7
NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS	8
GENERAL INFORMATION	8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	8
FINANCIAL RISK MANAGEMENT	18
ACCOUNTING ESTIMATES AND JUDGMENTS	19
SEGMENT REPORTING	20
PROPERTY, PLANT AND EQUIPMENT	23
INTANGIBLE ASSETS	24
FINANCIAL INSTRUMENTS	25
AVAILABLE-FOR-SALE FINANCIAL ASSETS	28
INVESTMENTS IN SUBSIDIARIES	28
INVENTORIES	29
TRADE RECEIVABLES	30
OTHER RECEIVABLES	30
CASH AND CASH EQUIVALENTS	31
SHARE CAPITAL	31
OTHER RESERVES	31
BORROWINGS	32
RETIREMENT BENEFIT OBLIGATIONS	33
TRADE AND OTHER PAYABLES	33
PROVISION FOR OTHER LIABILITIES AND CHARGES	33
OTHER INCOME	34
OTHER EXPENSES	34
EXPENSES BY NATURE	34
EMPLOYEE BENEFIT EXPENSES	35
OPERATING LEASING	35
FINANCE EXPENSES	35
INCOME TAX	35
EARNINGS PER SHARE	36
DIVIDENDS	36
COMMITMENTS	36
CONTINGENT LIABILITIES	36
RELATED PARTY TRANSACTIONS	37
EXCHANGE RATES OF PRINCIPAL CURRENCIES	39
TAXATION RISK	39
EVENTS AFTER THE REPORTING PERIOD	40
APPENDIX 1 – STAND-ALONE ANNUAL REPORT	
APPENDIX 2 STAND-ALONE ANNITAL ACCOUNTS	

Translation of the Auditor's Report issued in the Macedonian language

INDEPENDENT AUDITORS' REPORT

TO THE MANAGEMENT BOARD AND THE SHAREHOLDERS OF ALKALOID AD SKOPJE

We have audited the accompanying standalone financial statements (page 3 to 41) of ALKALOID AD Skopje (the "Company"), which comprise the standalone statement of financial position as at December 31, 2021, and the standalone statement of profit or loss, standalone statement of comprehensive income, standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information ("financial statements").

Management's Responsibility for the Standalone Financial Statements

Management is responsible for the preparation and fair presentation of these standalone financial statements in accordance with the International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of standalone financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We conducted our audit in accordance with the International Standards of Auditing, as applicable in the Republic of North Macedonia. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the standalone financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the standalone financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the standalone financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the standalone financial statements present fairly, in all material respects the financial position of ALKALOID AD Skopje as of December 31, 2021, and its financial performance and its cash flows for the year then ended in accordance with the accounting regulations prevailing in the Republic of North Macedonia.

(Continued)

INDEPENDENT AUDITORS' REPORT

TO THE MANAGEMENT BOARD AND THE SHAREHOLDERS OF ALKALOID AD SKOPJE (continued)

Emphasis of matter

We draw attention to Note 35 "Subsequent Events" of the financial statements, which describes potential effects of recent Russia's military actions on Ukraine territory on the Company's business operations. Our opinion is not modified in respect of this matter.

Report on Other Legal and Regulatory Requirements

Management is responsible for the preparation of the Company's annual report and the Company's annual account in accordance with the Company Law, which were adopted and approved by the management of the Company as of 14 February 2022 and that the Company is obliged to submit to the Central Registry of the Republic of North Macedonia. Our responsibility is to express an opinion on the consistency of the annual report with the annual account and the financial statements of the Company. We have performed our audit procedures in accordance with the Audit Law of the Republic of North Macedonia and International Standard on Auditing 720 – The Auditor's Responsibilities Relating to Other Information in Documents Containing Audited Financial Statements. In our opinion, the historical financial information disclosed in the annual report is consistent with the annual account and the accompanying audited financial statements of the Company for the year ended December 31, 2021.

Aleksandar Arizanov Certified auditor Director Sanja Arizanov Certified auditor

March 2, 2022 Deloitte DOO Skopje

^{*} This is an English translation of the original Independent Auditors' Report issued in the Macedonian language and is not to be signed. This translation is provided for references purposes only

(In thousands of Denar)

STAND-ALONE STATEMENT OF FINANCIAL POSITION

	As at 31 Decemb		ecember
	Note	2021	2020
Assets			_
Non-current assets			
Property, plant and equipment	6	6,261,707	5,951,609
Intangible assets	7	1,894,847	1,826,191
Available-for-sale financial assets	9	8,867	7,114
Investments in subsidiaries	10	513,278	513,278
Other non-current assets	13	133,429	61,980
		8,812,128	8,360,172
Current assets		0,012,120	0,000,172
Inventories	11	3,067,391	2,850,915
Trade receivables	12	2,291,657	2,384,754
Other receivables	13	220,969	211,303
Cash and cash equivalents	14	267,170	144,421
Cush und cush equivalents		5,847,187	5,591,393
Total assets		14,659,315	13,951,565
Equity			
Capital and reserves			
Share capital	15	2,220,127	2,220,127
Treasury shares		(109,285)	(109,285)
Legal reserves		596,146	596,146
Other reserves	16	1,688,236	1,686,483
Retained earnings		7,042,743	6,323,541
3		14,437,967	10,717,012
Non-current liabilities			
Non-current borrowings	17	661,083	604,335
Retirement benefit obligations	18	56,502	48,546
<u> </u>		717,585	652,881
Current liabilities		,	,
Trade and other payables	19	2,193,929	2,176,078
Income tax		9,997	19,588
Current borrowings	17	299,837	386,006
<i>6</i>		2,503,763	2,581,672
Total liabilities		3,221,348	3,234,553
Total equity and liabilities		14,659,315	13,951,565

The accompanying notes form an integral part of these stand-alone financial statements.

These stand-alone financial statements were approved by the Company's Managing Board on 14 February 2022.

Approved and signed on behalf of Alkaloid AD Skopje by:

Zhivko Mukaetov Viktor Stojcevski General Manager Finance Manager

(In thousands of Denar)

STAND-ALONE STATEMENT OF PROFIT OR LOSS

		Year ended	31 December
	Notes	2021	2020
Sales	5	9,559,755	9,188,259
Cost of sales	23	(5,743,172)	(5,534,946)
Gross profit		3,816,583	3,653,313
Research and development expenses	23	(151,663)	(121,368)
Selling and marketing expenses	23	(1,910,559)	(1,804,097)
Administrative expenses	23	(563,260)	(466,502)
Provision for other liabilities and charges	20	(7,956)	(9,023)
Other income	21	456,436	409,714
Other expenses	22	(234,989)	(399,309)
Operating profit		1,404,592	1,262,728
Finance expenses (net)	26	(16,750)	(14,714)
Profit before income tax		1,387,842	1,248,014
Income tax	27	(106,436)	(105,363)
Profit for the year		1,281,406	1,142,651
Earnings per share (in Denar)			
- Basic	28	911.70	811.00

(In thousands of Denar)

STAND-ALONE STATEMENT OF COMPREHENSIVE INCOME

		Year ended	31 December
	Notes	2021	2020
Profit for the year		1,281,406	1,142,651
Other comprehensive income: Fair value gain on investments	16	1,753	(297)
Other comprehensive income, net of tax		1,753	(297)
Total comprehensive income for the year		1,283,159	1,142,354

(In thousands of Denar)

STAND-ALONE STATEMENT OF CHANGES IN EQUITY

			For the ye	ear ended D	ecember 31	
	Share	Treasury	Legal	Other	Retained	75.4.1
	capital	shares	reserves	reserves	earnings	Total
As at January 1, 2020	2,220,127	(98,805)	596,146	1,686,780	5,686,873	10,091,121
Purchase of treasury shares	-	(10,480)	-	-	-	(10,480)
Dividend payment and tax on dividend paid out	-	-	-	_	(505,983)	(505,983)
Profit for the year		-	-	-	1,142,651	1,142,651
Statement of comprehensive income				(205)		(207)
Fair value gain on investments (Note 9)		-	-	(297)	-	(297)
		-		(297)	-	(297)
As at December 31, 2020	2,220,127	(109,285)	596,146	1,686,483	6,323,541	10,717,012
Purchase of treasury shares	-	-	-	-	-	-
Dividend payment and tax on dividend paid out	-	-	-	-	(562,204)	(562,204)
Profit for the year		_		-	1,281,406	1,281,406
Statement of comprehensive income						
Fair value gain on investments (Note 9)	-	-	-	1,753	_	1,753
. ,		-	-	1,753	-	1,753
As at December 31, 2021	2,220,127	(109,285)	596,146	1,688,236	7,042,743	11,437,967

(In thousands of Denar)

STAND-ALONE STATEMENT OF CASH FLOWS

	Year ended 31 December	
	2021	2020
Cash flows from operating activities	0.004.474	0.212.024
Cash receipts from customers	9,984,474	9,212,834
Cash paid to suppliers and employees	(8,274,926)	(7,823,550)
Cash generated from operations	1,709,548	1,389,284
Cash flows from investing activities		
Purchases of property, plant and equipment	(1,204,125)	(1,435,718)
Investments in subsidiaries (Note 10)	-	(3,301)
Dividends received	120,975	83,769
Subsidies received	176,694	121,190
Other payments to employees	(63,386)	(55,123)
Net cash used in investing activities	(969,842)	(1,289,183)
Cash flows from financing activities		
Proceeds from borrowings	2,040,810	2,415,943
Repayments of borrowings	(2,078,688)	(1,978,425)
Interest paid	(16,867)	(15,599)
Purchase of treasury shares	(10,007)	(10,480)
Dividends paid to shareholders, tax on dividends paid out and other profit	-	(10,460)
allocations	(562,212)	(506,301)
Net cash used in financing activities	(616,957)	(94,862)
<u>-</u>		
Net (decrease)/increase in cash and cash equivalents	122,749	5,239
Cash and cash equivalents at beginning of year	144,421	139,182
Cash and cash equivalents at the end of year	267,170	144,421
Cash and cash equivalents at the end of year	267,170	144,421



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

1. GENERAL INFORMATION

Alkaloid AD Skopje (the "Company") produces and sells a wide range of pharmaceutical, chemical and cosmetic products, as well as goods from herbal origin. The Company has nineteen subsidiaries and one Foundation in the Republic of North Macedonia and other countries. For the list of the subsidiaries please refer to Note 10.

Alkaloid AD Skopje, the parent company, is a joint stock company, incorporated and registered (with its head office) in the Republic of North Macedonia. The registered address of the Company is: Aleksandar Makedonski 12

1000 Skopje,

Republic of North Macedonia

The shares of Alkaloid AD Skopje have been listed on the Macedonian Stock Exchange, since 2002.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these stand-alone financial statements are set out below. These policies have been consistently applied to all the years presented.

2.1. Basis of Preparation and Presentation of Stand-alone Financial Statements

Pursuant to the provisions of the Company Law (Official Gazette nos. 28/04, 84/05, 71/06, 25/07, 87/08, 17/09, 23/09, 42/10, 48/10, 8/11, 21/11, 24/11, 166/12, 70/13, 119/13, 120/13, 187/13, 13/14, 41/14, 138/14, 88/15, 192/15, 6/16, 30/16, 61/16, 64/18, 120/18, 195/2018, 225/2018, 239/2018, 290/20 and 215/21) legal entities in the Republic of North Macedonia are required to maintain their books of account and to prepare their financial statements in conformity with the International Financial Reporting Standards published in the Official Gazette of the Republic of North Macedonia.

A newly-issued Rulebook for Chart of Accounts (Official Gazette nos. 159/09, 164/10 and 107/11) was adopted on December 29, 2009. It contains: the International Accounting Standards ("IAS"), International Financial Reporting Standards ("IFRS") and related interpretations issued by the Standing Interpretation Committee ("SIC") and the International Financial Reporting Interpretations Committee ("IFRIC") determined and issued by the International Accounting Standards Board ("IASB") as of January 1, 2009. This Rulebook has been effective from January 1, 2010.

Until the date of preparation of the accompanying financial statements, the amendments of the International Financial Reporting Standards ("IFRS/ISA") and interpretations of IFRIC in effect for the annual periods beginning on or after January 1, 2009, have not yet been translated and published in the Republic of North Macedonia.

Given the potentially material effects which the departures of accounting regulations applicable in Republic of North Macedonia from the International Financial Reporting Standards may have on the fairness of presentation made in the Company's stand-alone financial statements, the accompanying stand-alone financial statements cannot be treated as a set of stand-alone financial statements prepared in accordance with the International Financial Reporting Standards.

However, the accompanying stand-alone financial statements of the Company are presented in the format prescribed under the "Guidelines on the Prescribed Form and Content of the Annual Financial Statements" (Official Gazette of the Republic of North Macedonia no, 60/14). Such statements represent a set of financial statements that differ in some respects from the presentation of certain amounts as required under the provisions of adopted IAS 1 - "Presentation of Financial Statements".



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.1. Basis of Preparation and Presentation of the Stand-alone Financial Statements (Continued)

The accompanying stand-alone financial statements were prepared at historical cost principle, unless otherwise stipulated in the accounting policies presented hereunder. In the preparation of the accompanying stand-alone financial statements, the Company adhered to the accounting policies described in Note 2.

All amounts in the Company's stand-alone financial statements are stated in thousands of Macedonian Denars (MKD). The Denar is the official reporting currency in the Republic of North Macedonia.

The preparation of the stand-alone financial statements in accordance with the Law on Trade Companies and the Rulebook on Accounting requires the application of estimates and assumptions by the management of the Company, which affect the positions expressed in the stand-alone financial statements. Although management estimates are based on reasonable information and knowledge of events and activities, the actual results may differ from those estimated. Management estimates are shown in Note 4.

2.2. Subsidiaries

Subsidiaries are all legal entities over which the Company has the power to govern the financial and operating policies generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another Company. The cost of acquisition is measured at fair value of the assets given. The investments in subsidiaries are recorded at cost less any eventual impairment.

2.3. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the Managing Board. The Managing Board is responsible for strategic decisions for each segment. At December 31, 2021, the Company was organized on a worldwide basis into four reportable segments:

- Pharmaceuticals Production and sales of medicines for human use, medicines for veterinary use and pharmaceutical raw materials;
- Chemicals
 Production and sales of chemicals products;
- Cosmetics Production and sales of cosmetics;
- Botanicals Production and sales of botanicals products,

The pharmaceutical overall production program of the products of Alkaloid Pharmaceuticals is comprised of the following pharmaceutical forms:

- Oral hard dosage forms: Tablets conventional and modified release, film-tablets, coated tablets, sub-lingual tablets, capsules, dry powder for oral suspension.
- Liquid dosage forms for oral administration: Solutions for oral administration, syrups and suspensions.
- Topical preparations: Ointments, creams, solutions, gels, sprays, vaginal pessaries, suppositories.
- Sterile dosage forms: Parenteral small-volume, eye drops and ointments for eyes.

Besides the capacities for manufacturing finished pharmaceutical products, Alkaloid-Pharmaceuticals also has facilities for extraction of opioids which include production of morphine and its derivatives as pharmaceutical raw materials.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.3. Segment reporting (Continued)

Alkaloid Chemical products today are developed program for the production of chemicals and organic and non-organic reagents, with pa, puriss, purum and with pharmacopeias qualities. They are suitable for laboratories within institutions, faculties, clinics, the pharmaceutical and cosmetic industry, as well as in the production processes of other industries.

Alkaloid's Cosmetics Unit develops and produces skincare products, children's skincare, soaps, hair care products, dental care products, men's perfume collection, women's perfume collection, as well as household cleaners. The ingredients that are used in the products are purchased from suppliers that satisfy our high-quality standards and are in accordance with the requirements of the European directive for quality cosmetic products.

The activities in the Botanical unit consists of Processing blending and packing herbal materials like roots, leaves, fruits, seeds etc.

Segment revenue is revenue reported in the company's income statement that is directly attributable to a segment and the relevant portion of the company income that can be allocated on a reasonable basis to a segment.

Segment expense is an expense resulting from the operating activities of a segment that is directly attributable to the segment and the relevant portion of an expense that can be allocated on a reasonable basis.

Net operating assets consist primarily of property, plant and equipment, intangible assets, inventories and receivables less operating liabilities. Company's net financial assets principally consist of net liquidity (cash, cash equivalents and other current financial assets less financial debts) and deferred and current taxes.

The accounting policies of the reportable segments are the same as the Company's accounting policies. This is the measure reported to the managing board for decision making purposes in the field of resource allocation and assessment of segment performance.

2.4. Foreign currency translation

Functional and presentation currency

The Stand-alone financial statements are presented in thousands of Macedonian Denar, which is the Company's functional and presentation currency.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange differences resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.5. Property, plant and equipment

The property plant and equipment, except the land, are initially recorded at cost. The land is subsequently stated at fair value, based on the appraisal performed by external independent appraisers. Other property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition.

Subsequent costs are included in the asset's carrying amount, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Increases in the carrying amount arising on revaluation of land and buildings are recognized in other comprehensive income, credited to other reserves in shareholders' equity. Decreases that offset previous increases of the same asset are charged against other reserves directly in equity; all other decreases are charged to the consolidated income statement. The revaluation surplus is transferred to retained earnings upon ultimate disposal of revaluated asset.

Land is not depreciated. Depreciation on other assets is calculated using the straight-line method to allocate their cost or revalued amounts to their residual values over their estimated useful lives, as follows:

Buildings	10 - 40	years
Machinery	10 - 20	years
Vehicles	4	years
Furniture, fittings and equipment	3 - 10	years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting sheet date.

An asset's carrying amount is written down immediately to its recoverable amount if higher than its estimated recoverable amount.

The carrying amount of disposed property, plant and equipment items is eliminated from the standalone statement of financial position together with the carrying amount of accumulated depreciation. Gains and/or losses on disposals are determined as the difference between the proceeds on disposal and the carrying amount of the assets and included in the stand-alone income statement.

2.6. Intangible assets

Intangible assets are consisted of trademarks, licenses and software. Intangible assets are carried at cost less accumulated amortization. The cost value includes the invoiced expense of purchased intangible assets increased by all expenditures that are directly attributable to the acquisition of the items.

Amortization is calculated using the straight-line method to allocate the cost of trademarks, licenses and software over their estimated useful lives, maximum of 10 years.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.6. Intangible assets (Continued)

Intangible assets acquired separately

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives, i.e. up to 10 years. The estimated useful life and amortization method are reviewed at the end of each reporting period.

Internally-generated intangible assets - research and development expenditure

Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally-generated intangible asset arising from development is recognized if, and only if, all of the following have been demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or sale;
- The intention to complete the intangible asset and use or sell it;
- The ability to use or sell the intangible asset;
- How the intangible asset will generate probable future economic benefits;
- The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- The ability to measure reliably the expenditure attributable to the intangible asset during its development,

The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

Patents

Patents are measured initially at purchase cost and are amortized on a straight-line basis over their estimated useful lives of 10 years.

2.7. Impairment of non-financial assets

Assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment. Assets that are subject to amortization and depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at each reporting date.

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.8. Financial assets

The Company classifies its financial assets in the following categories: loans and receivables and available-for-sale. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of its financial assets at initial recognition and reevaluates this designation at every reporting date.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the balance sheet date. These are classified as non-current assets, Loans and receivables are classified as trade and other receivables in the Statement of financial position (Note 2.10).

Available-for-sale financial assets

Available-for-sale financial assets are included in non-current assets unless management intends to dispose of the investment within 12 months of the balance sheet date.

Regular purchases and sales of investments are recognized on trade-date - the date on which the Company commits to purchase or sell the asset. The purchase value of investments includes transaction costs. Investments are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Available-for-sale financial assets are subsequently carried at fair value. The Company also has investments in unlisted shares that are not traded in an active market but that are also classified as AFS financial assets are stated at cost, because the Company consider that cost approximates their fair value. Loans and receivables are carried at amortized cost using the effective interest method.

Gains or losses arising from changes in the fair value of the available-for-sale financial assets are presented in the equity and statement of comprehensive income, except for the impairment losses of the financial assets, calculated interests using the effective interest method and foreign exchange differences which are recognized in the profit and loss statement.

When securities classified as available-for-sale are sold or impaired, the accumulated fair value adjustments recognized in equity are included in the income statement. Dividends on available-for-sale equity instruments are recognized in the income statement when the Company's right to receive payments is established.

The fair values of quoted investments are based on last traded prices. Investments in equity instruments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured are recognized at cost, less impairment.

The Company assesses at each balance sheet date whether there is objective evidence that a financial asset is impaired. In the case of equity securities classified as available-for-sale, a significant or prolonged decline in the fair value of the security below its cost is considered an indicator that the securities are impaired. If any such evidence exists for available-for-sale financial assets, the cumulative loss - measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that financial asset previously recognized in profit or loss - is removed from equity and recognized in the income statement. The method for evaluation of impairment of trade receivables is explained in Note 2.10.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.9. Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the actual cost method. The cost of finished goods and work in progress comprises direct production costs and related production overheads. The net realizable value is the estimated selling price in the ordinary course of business, less estimated cost of completion and applicable variable selling expenses.

2.10. Trade receivables

Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the trade receivable is impaired.

The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognized in the income statement within 'Selling and marketing costs'.

2.11. Cash and cash equivalents

Cash and cash equivalents include cash in balances held on bank accounts and cash in hand.

2.12.Share capital

Ordinary shares are classified as equity. Purchases of the Company's equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs is deducted from equity attributable to the Company's equity holders until the shares are cancelled, reissued or disposed of. Where such shares are subsequently sold or reissued, any consideration received, net of any directly attributable incremental transaction costs and are included in equity attributable to the Company's equity holders.

2.13.Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting sheet date.

2.14.Trade and other payables

All financial liabilities are measured subsequently at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortized cost of a financial liability.

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.15.Income tax

Current income tax is calculated and paid in accordance with the Income tax Law. The estimated tax liability is paid in advance on a monthly basis. The final tax is payable at the rate of 10% applicable to the taxable income, which is the profit as determined in the Statement of comprehensive income adjusted for certain tax deductible items as defined by the local tax legislation.

Deferred tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts reported in the stand-alone financial statements. However, the deferred income tax is not accounted for, if arising from initial recognition of an asset or a liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred tax is calculated using the current tax rate. Deferred tax liabilities are recognized for all taxable time differences. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred tax assets are provided on temporary differences arising on investments in subsidiaries excepts where timing of the reversal of temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future.

2.16. Employee benefits

Pension liabilities

The Company has both defined benefit and defined contribution plans.

- Defined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent on one or more factors such as age, years of service and compensation.
- A defined contribution plan is a pension plan under which the Company pays contributions into publicly and privately administered pension plans on a mandatory basis. The Company has no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

The liability recognized in the Stand-alone statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating to the terms of the related pension liability.

The Company pays contributions to publicly or privately administered pension insurance plans on a mandatory basis. The Company has no further payment obligations once the contributions have been paid. The contributions are recognized as employee benefit expense when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.16. Employee benefits(Continued)

Termination benefits

Termination benefits are payable when employment is terminated by the Company before the normal retirement date, or whenever an employee accepts voluntary redundancy in exchange for these benefits. The Company recognizes termination benefits when it is demonstrably committed to either: terminating the employment of current employees according to a detailed formal plan without possibility of withdrawal; or providing termination benefits as a result of an offer made to encourage voluntary redundancy. The Company recognizes a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

Profit-sharing and bonus plans

The Company recognizes a liability and an expense for bonuses and profit-sharing, based on a decision of a Managing Board. The Company recognizes a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

2.17.Provisions

Provisions for environmental restoration, restructuring costs and legal claims are recognized when the Company has a present legal or constructive obligation as a result of past events; it is more likely than not that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation.

2.18. Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods and services in the ordinary course of the Company's activities. Revenue is shown, net of value-added tax, estimated returns, discounts and rebates. Revenue is recognized as follows:

Sales of goods

Sales of goods are recognized when a Company has delivered products to the customer; the customer has accepted the products and collectability of the related receivables is reasonably assured.

Sales of services

Sales of services are recognized in the accounting period in which the services are rendered, by reference to completion of the specific transaction assessed on the basis of the actual service provided as a proportion of the total services to be provided.

Interest income

Interest income is recognized on a time-proportion basis using the effective interest method. When a receivable is impaired, the Company reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at original effective interest rate of the instrument, and continues unwinding the discount as interest income.

Dividend income

Dividend income is recognized when the right to receive payment is established.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2.19. Dividends

Dividend distribution to the Company's shareholders is recognized as a liability in the Company's stand-alone financial statements in the period in which the dividends are approved by the Company's shareholders.

2.20.Government grants

Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related costs for which the grants are intended to compensate. Specifically, government grants whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets are recognized as deferred income in the stand-alone statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets. Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognized in profit or loss in the period in which they become receivable.

2.21.Going concern principle

The rapid spread of the Covid-19 virus and its economic effects in the Republic of North Macedonia and globally may result in a reassessment of assumptions and estimates, which could have an impact of material adjustment to the present value of assets and liabilities over the following business period. At this stage, management is unable to assess the effect with certainty, as new events occur on a daily basis.

Based on the performed analyzes according to the current developments, the Company determined that difficulties in the operation related to liquidity and servicing of liabilities to suppliers currently are not expected.

Until the date of issuance of the financial statements, no information has been received regarding cancellation of a contract due to the current situation. The Company continued to operate at full capacity and revenues exceeded budgeted revenues.

For the year ended 31.12.2021, the Company achieved a net profit of 1,281,406 thousand Denars (2020: 1,142,651 thousand Denars). The Company in the previous periods achieved significant business and financial results, thereby expects stable revenues and that the increase in costs will be with a lower trend than the increase in revenues. As a result, the accompanying stand-alone financial statements have been prepared in accordance with the going concern principle which implies that the Company will continue to operate in the foreseeable future.

Furthermore, the Company established a Crisis committee, which on a daily basis monitors all emergency measures and conditions in the country, macroeconomic indicators, established measures, global developments and based on that prepares an action plan.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

3. FINANCIAL RISK MANAGEMENT

3.1. Financial risk factors

The Company's activities expose it to a variety of financial risks: market risk (including currency risk, fair value interest rate risk and price risk), credit risk, liquidity risk and cash flow interest rate risk. The Company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company's financial performance. The financial risk management is performed by the Company's financial department, based on Decisions from Managing Board.

Market risk

a) Foreign exchange risk

The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures. To manage the foreign exchange risk the Company provides sufficient cash in foreign currencies held on bank accounts in order to maintain its future commercial transactions.

b) Price risks

The Company is exposed to equity securities price risk because of Investments in equity instruments held by the Company. The Company is not exposed to commodity price risk.

Credit risk

The Company has no significant concentrations of credit risk. It has policies in place to ensure that wholesale sales of products are made to customers with an appropriate credit history. Trade receivables consist of a large number of balances. The Company has policies that limit the amount of credit exposure.

Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities.

Interest risk

As the Company has no significant interest-bearing assets, the Company's income and operating cash flow are substantially independent of changes in market interest rates.

The Company's interest rate risk arises from borrowings. The Company has no specific policy, but in direct negotiation with lenders attempts to reduce interest rate risk. Interest rates of long-term borrowings are lower than short term. Interest rates on short term borrowings are decreased in respect of previous year.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

3. FINANCIAL RISK MANAGEMENT (Continued)

3.2. Fair value assessment

The fair value of available-for-sale financial assets traded in active markets is based on quoted market prices at the balance sheet date. The quoted market price used for financial assets held by the Company is the last traded price.

The fair value of financial instruments that are not traded in an active market is determined by assumptions that are based on public information for recent arm's length transactions or reference to other instruments that are substantially the same.

The nominal value less impairment provision of trade receivables and payables are assumed to approximate their fair values. The assumptions of the Company are based on past experience and other factors, including the expectation of future events that are probable at the reporting date.

3.3. Capital risk management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to minimize the cost of capital. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

4. ACCOUNTING ESTIMATES AND JUDGMENTS

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Depreciation and amortization rates

The calculation of depreciation and amortization rates are based on the economic useful life of property, plant and equipment. Based on the current estimates, the Company assesses the economic useful life of property, plant and equipment on annual basis.

Fair value of land

The Company tests annually whether fair value of land and buildings has suffered material changes compared with their fair value as assessed in the last appraisal. The Company estimation is that the difference between their fair value recorded into the books and the current market value is not material, and do not affect the result.

Fair value of financial assets

The available-for-sale financial assets that are not traded in an active market on the Macedonian Stock Exchange are stated at their cost. The Company estimation is that the difference between their fair value and cost is not material, and do not affect the result taking in consideration that this financial assets are insignificant both in the books in the Company and as a percentage of participation in the issuer capital.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

4. ACCOUNTING ESTIMATES AND JUDGMENTS (Continued)

Impairment of Trade and Other Receivables

The allowance for impairment of doubtful receivables is formed based on the estimated losses arising from customer's default. The management's assessment is based on the ageing analysis of accounts receivable, historical write-offs, customer creditworthiness and changes in the terms of sale, identified upon determining the adequacy of allowance for impairment of doubtful receivables. This includes the assumptions on future customer behavior and future collections arising therefrom. The management believes that no allowance for impairment, except for the provisions already included in the financial statements, is necessary

Provisions

Provisions in general are highly judgmental. The Company assesses the probability of an adverse event as a result of a past event to happen. The Company is rather prudent in these assessments, but due to the high level of uncertainty, in some cases the evaluation may not prove to be in line with the eventual outcome of the case.

Estimates for accounting for employee benefits

IAS19, Employee Benefits, requires that certain assumptions are made in order to determine the amount to be recorded for retirement benefit obligations. These are mainly actuarial assumptions such as expected inflation rates, long-term increase in health care costs, employee turnover and discount rates. Substantial changes in the assumed development of any one of these variables may change the Company's retirement benefit obligation.

5. SEGMENT REPORTING

Segment information reported to the Management Board is based on product types and customer categories.

Principal product types are pharmaceutical and non-pharmaceutical products (chemicals, cosmetics and botanicals). The principal customer's category for the Company's products are wholesalers.

Segments revenues and results as of 31 December are as follows:

Segment revenue		Segment opera	iting profit
2021	2020	2021	2020
8,003,675	7,582,603	1,369,283	1,138,741
331,019	289,039	35,557	33,276
973,843	927,830	43,239	34,140
251,218	388,787	(43,487)	56,571
9,559,755	9,188,259	1,404,592	1,262,728
	_	(16,750)	(14,714)
		1,387,842	1,248,014
		(106,436)	(105,363)
		1,281,406	1,142,651
	2021 8,003,675 331,019 973,843 251,218	2021 2020 8,003,675 7,582,603 331,019 289,039 973,843 927,830 251,218 388,787	2021 2020 8,003,675 7,582,603 1,369,283 331,019 289,039 35,557 973,843 927,830 43,239 251,218 388,787 (43,487) 9,559,755 9,188,259 1,404,592 (16,750) 1,387,842 (106,436)



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

5. SEGMENT REPORTING (Continued)

Segment assets and liabilities for the year ended December 31 are as follows:

Segment assets

	2021	2020
Pharmaceutical product	13,719,363	12,724,837
Chemical products	544,137	529,014
Cosmetic products	333,099	461,617
Botanical products	134,060	236,097
Total assets	14,730,659	13,951,565
Segment liabilities	2021	2020
Pharmaceutical product	2,940,092	2,755,543
Chemical products	135,796	122,929
Cosmetic products	169,244	306,640
Botanical products	47,560	49,441
Total liabilities	3,292,692	3,234,553

Other segment information for the year ended December 31 are as follows

	Depreciation and amortization		Addition to no asset	
	2021	2020	2021	2020
Pharmaceutical product	703,542	622,499	1,255,281	1,255,281
Chemical products	17,354	16,298	13,730	13,730
Cosmetic products	29,451	28,704	167,038	167,038
Botanical products	35,837	29,621	113,166	113,166
Total liabilities	786,184	697,122	1,549,215	1,549,215

Geographical information

The Republic of North Macedonia is the domicile country of the Company where the significant part of the business activities have been held.

	Sales revenue		Non-currer	nt assets
	2021	2020	2021	2020
Republic of North Macedonia	3,122,591	3,030,385	8,156,554	7,777,800
Serbia	1,846,174	1,754,980	-	-
Bosnia and Herzegovina	845,890	866,891	-	-
Croatia	550,548	509,497	-	-
Kosovo	425,677	411,961	-	-
Other countries	2,768,875	2,614,545	_	_
Total	9,559,755	9,188,259	8,156,554	7,777,800

Geographical information about sales revenue is based on the customers' origin. Non-current assets include property, plant and equipment and Intangible assets.

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

5. SEGMENT REPORTING (Continued)

Information about major customers

The sales of Pharmaceutical products are spread over many countries and customers. There are no major customer shares in the direct sales of Pharmaceutical products.

In the sales of Chemical products, there is one major customer with a share of 28.5% (2020: 15.6%) in direct sales.

In the sales of Cosmetic products, there is one major customer with a share of 16.1% (2020: 16.4%) in direct sales.

In the sales of Botanical products, there is one major customer with a share of 32.5% (2020: 59.2%) in direct sales.

Sales by category	2021	2020
Sales of goods	7,632,045	7,324,714
Sales of commodities	1,750,687	1,721,615
Revenue from services	177,023	141,930
	9,559,755	9,188,259

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

6. PROPERTY, PLANT AND EQUIPMENT

	Land	Buildings	Equipment	Construction in progress	Total
Cost or valuation	Land	Dunungs	Equipment	in progress	1000
At January 1, 2020	1,659,696	3,375,332	4,371,849	245,691	9,652,568
Additions	-	32	20,365	1,126,843	1,147,240
Transfer from construction in		32	20,303	1,120,013	1,117,210
progress	1,971	269,595	777,901	(1,049,467)	-
Elimination of cost	(38)	(5,487)	(1,085)		(6,610)
As at December 31, 2020	1,661,629	3,639,472	5,169,030	323,067	10,793,198
Accumulated depreciation					
At January 1, 2020	-	1,835,712	2,620,164	-	4,455,876
Depreciation charge		84,351	307,777		392,128
Elimination of accumulated					
depreciation		(5,487)	(928)		(6,415)
As at December 31, 2020	<u> </u>	1,914,576	2,927,013		4,841,589
Not hook volve og et December 21					
Net book value as at December 31, 2020	1,661,629	1,724,896	2,242,017	323,067	5,951,609
2020	1,001,027	1,724,000	2,242,017	323,007	3,731,007
At January 1, 2021	1,661,629	3,639,472	5,169,030	323,067	10,793,198
Reclassification		(104)	104	(2,407)	(2,407)
Additions	-		24,714	759,243	783,957
Transfer from construction in					
progress	11,076	198,260	631,417	(840,753)	-
Elimination of cost		(600)	(112,700)		(113,300)
As at December 31, 2021	1,672,705	3,837,028	5,712,565	239,150	11,461,448
Accumulated depreciation					
At January 1, 2021	-	1,914,576	2,927,013	_	4,841,589
Reclassification					
Depreciation charge	-	92,417	373,913	-	466,330
Elimination of accumulated					
depreciation		(316)	(107,862)		(108,178)
As at December 31, 2021	<u> </u>	2,006,677	3,193,064		5,199,741
Net book value as at December 31,					
2021	1,672,705	1,830,351	2,519,501	239,150	6,261,707

Land was revalued as at 31 December 2019 by an independent appraiser. The revaluation surplus/deficit was credited to other reserves within shareholders' equity (Note 16).



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

7. INTANGIBLE ASSETS

	Trademarks and licenses	Software and Internally generated intangibles	Other assets	Construction in progress	Total
Cost or valuation					
At January 1, 2020	365,287	2,636,704	91,704	72,148	3,165,843
Additions	-	6,593	-	395,382	401,975
Transfer from construction in					
progress	1,951	378,043	5,124	(385,118)	
As at December 31, 2020	367,238	3,021,340	96,828	82,412	3,567,818
Accumulated depreciation					
At January 1, 2020	339,334	1,041,417	55,882		1,436,633
Depreciation charge	8,643	288,296	8,055		304,994
As at December 31, 2020	347,977	1,329,713	63,937		1,741,627
Net book value as at December 31, 2020	19,261	1,691,627	32,891	82,412	1,826,191
Cost or valuation					
At 1 January 2021	367,238	3,021,340	96,828	82,412	3,567,818
Reclassification				2,407	2,407
Additions		4,866		381,508	386,374
Transfer from construction in					
progress	335	409,908	6,583	(416,826)	-
Elimination of assets		(5,377)		(269)	(5,646)
As at 31 December 2021	367,573	3,430,737	103,411	49,232	3,950,953
Accumulated depreciation					
At 1 January 2021	347,977	1,329,713	63,937		1,741,627
Depreciation charge	7,073	304,913	7,868		319,854
Elimination of assets		(5,375)			(5,375)
As at 31 December 2021	355,050	1,629,251	71,805		2,056,106
Net book value as at 31 December 2021	12,523	1,801,486	31,606	49,232	1,894,847

The net book value of software is Denar 101,374 thousand (2020: Denar 113,418 thousand), and the rest of the amount is internally generated intangibles.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

8. FINANCIAL INSTRUMENTS

Capital risk management

The management of the Company reviews the capital structure on a regular basis.

	2021	2020
Debt Cash and cash equivalents	960,920 (267,170)	990,341 (144,421)
Net debt	693,750	845,920
Equity	14,437,967	10,717,012
Net debt to equity ratio	4.81%	7.89%

Categories of financial instruments and risk management objectives

The Company's principal financial instruments are cash and cash equivalents and trade receivables, as well as, borrowings and trade payables. In the normal course of operations the Company is exposed to the following risks:

Foreign currency risk

The Company undertakes certain transactions denominated in foreign currency in respect of sales of goods and services, purchase of raw materials, services and equipment and obtaining borrowings. The Company does not use any special financial instruments to hedge against this risk since no such instruments are in common use in the Republic of North Macedonia.

The carrying amounts of the Company's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

	Lial	Liabilities		ets
	2021	2020	2021	2020
EUR	478,551	723,469	2,081,531	1,785,433
RUR	-	-	388,466	561,172
USD	290,842	145,810	67,095	58,421
CHF	3,932	15,368	1,516	1,208
Other currencies	(803)	285	924	994

The Company is mainly exposed to Euro and Russian Ruble currencies.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

8. FINANCIAL INSTRUMENTS (Continued)

The following table details the Company's sensitivity analysis to a 10% increase and decrease in the Macedonian Denar against the relevant foreign currency. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end. A positive amount below indicates an increase in profit and equity, while a negative amount indicates a decrease.

	Increase of 10% in MKD		Decrease of 10°	% in MKD
_	2021	2020	2021	2020
EUR	(160,298)	(106,196)	160,298	106,196
RUR	(38,847)	(56,117)	38,847	56,117
USD	22,375	8,739	(22,375)	(8,739)
CHF	242	1,416	(242)	(1,416)
Other currencies	(173)	(71)	173	71
Impact on the profit or loss and equity	(176,701)	(152,229)	176,701	152,229

The Company's sensitivity to foreign currency rates has increased during the current period mainly due to the increase in foreign trade receivables.

Interest rate risk

The Company is exposed to interest risk arising from variable interest rate on borrowings, which depend on the financial market trends.

The sensitivity analyses below have been determined based on the interest rate exposure as a result of a 10% increase or decrease in rates on foreign borrowings at the reporting date. A positive amount below indicates an increase in the profit and equity, while a negative amount indicates a decrease.

Foreign currency risk

	Increase of 10%		Decrease of 10%	
	2021	2020	2021	2020
Borrowings	1,675	1,465	(1,675)	(1,465)
Profit and loss and equity	(1,675)	(1,465)	1,675	1,465

Had the interest rates been 10% higher the Company's profit for the year ended December 31, 2021 and retained earnings would have decreased by Denar 1,675 thousand and vice versa, had the interest rates been 10% lower, the Company's profit for the year ended December 31, 2021 and retained earnings would have increased by Denar 1,675 thousand.



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

8. FINANCIAL INSTRUMENTS (Continued)

Liquidity risk


The management of the Company has responsibility for maintaining adequate liquidity. In certain cases, the Company uses short-term and long-term funding for liquidity purposes. The Company manages liquidity risk by maintaining adequate cash reserves, by continuously monitoring forecast and actual cash flows. At any time, the Company can draw additional borrowings from banks with relatively low interest rates, which reduce further liquidity risk.

The following tables detail the Company's remaining contractual maturities of its financial liabilities.

2021	Less than 1 month	1 - 3 months	3 - 12 months	12 - 60 months	Total
Trade payables Borrowings	767,502 22,139	714,952 49,278	104,545 228,420	7,016 661,083	1,594,015 960,920
	789,641	764,230	332,965	668,099	2,554,935
2020	Less than 1 month	1 - 3 months	3 - 12 months	12 - 60 months	Total
Trade payables Borrowings	908,147	665,892	105,002	5,643 604.335	1,684,684
\mathcal{E}	6,667	249,609	129,730	004,333	990,341

The following tables detail the Company's remaining contractual maturities of its financial assets:

2021	Less than 1 month	1 - 3 months	3 - 12 months	12 - 60 months	Total
Trade receivables	344,569	834,700	1,112,388	-	2,291,657
Cash and cash equivalents	267,170	-	-		267,170
	611,739	834,700	1,112,388	-	2,558,827
2020	Less than 1 month	1 - 3 months	3 - 12 months	12 - 60 months	Total
Trade receivables	498,048	1,016,503	870,203	-	2,384,754
Cash and cash equivalents	144,421				144,421
	642,469	1,016,503	870,203	-	2,529,175



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

9. AVAILABLE-FOR-SALE FINANCIAL ASSETS

	2021	2020
At January 1	7,114	7,411
Additions	1,769	572
Disposals	(16)	(869)
At 31 December	8,867	7,114
Available-for-sale financial assets consist of:		
	2021	2020
Available-for-sale financial assets in non-quoted companies	2,675	2,388
Available-for-sale financial assets in quoted companies	6,192	4,726
	8,867	7,114

Investments in securities available-for-sale consist of shares in companies and banks. Participation in their shares is below 10% of the registered equity.

Available-for-sale financial assets of quoted shares are presented by market value. The unlisted shares that are not traded in an active market are stated at cost, because the Company consider that cost approximates their fair value.

10. INVESTMENTS IN SUBSIDIARIES

<u>-</u>	2021	2020
Alkaloid DOO Beograd, Serbia	173,256	173,256
Alkaloid DOO Zagreb, Croatia	15,439	15,439
Alkaloid INT DOO Ljubljana, Slovenia	866	866
Alkaloid DOO Sarajevo, Bosnia and Herzegovina	39	39
Alkaloid EOOD Sofia, Bulgaria	2,748	2,748
ALK&KOS Shpk Prishtina, Kosovo	307	307
Alkaloidpharm SA Fribourg, Switzerland	5,429	5,429
Alkaloid USA LLC Columbus, Ohio USA	3,873	3,873
Alkaloid Kons DOOEL Skopje, N. Macedonia	130,154	130,154
Fund "Trajce Mukaetov" Skopje, N. Macedonia	-	_
Alkaloid DOO Podgorica, Montenegro	3,000	3,000
OOO Alkaloid RUS, Moscow, Russia	119,359	119,359
Alkaloid FARM DOO Ljubljana, Slovenia	461	461
Alkaloid Veledrogerija DOO Beograd, Serbia	7,720	7,720
Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia	2,616	2,616
Alkaloid ILAC TLS Istanbul, Turkey	308	308
ALKA-LAB DOO Ljubljana, Slovenia	43,081	43,081
Alkaloid Shpk Tirana, Albania	308	308
Alkaloid Kiev CO, LTD, Ukraine	2,157	2,157
Alkaloid LGL DOO, Zagreb	2,157	2,157
Alkaloid UK Limited	<u> </u>	
<u>-</u>	513,278	513,278

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

10. INVESTMENTS IN SUBSIDIARIES (Continued)

All subsidiaries are solely (100%) owned by the Company, except for the investment in Alkaloid USA which is an equity share of 49%. Although the investment of Alkaloid AD Skopje in Alkaloid USA LLC Columbus, Ohio USA is 49%, the Company exercises control over this entity.

In 2021 a new subsidiary was established in UK with a name Alkaloid UK LIMITED. In 2020 a new subsidiary was established in Croatia with a name Alkaloid LGL DOO, Zagreb. The subsidiaries are 100% owned by the Company.

In 2020 the company has increased its investment in one of its subsidiaries, in Alkaloidpharm SA Fribourg, Switzerland in the amount of 20 thousand Swiss francs. The subsidiary is 100% owned by the Company.

Alkaloid's representative offices in Russia, and Ukraine are included in the stand-alone financial statements of the Company.

11. INVENTORIES

	2021	2020
Raw materials	1,334,719	1,154,941
Spare parts	189	209
Tools and consumable supplies	4,541	2,653
Work in progress	323,176	332,653
Finished goods	1,079,011	996,425
Commodities	325,755	364,034
	3,067,391	2,850,915

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

12. TRADE RECEIVABLES

	2021	2020
Trade receivables	2,468,382	2,561,479
Less: provision for impairment of receivables	(176,725)	(176,725)
Trade receivables – net	2,291,657	2,384,754
Changes in the provision are as follows:		
-	2021_	2020
At January 1	176,725	177,046
Collected bad and doubtful debts		(321)
As at December 31	176,725	176,725
	2021	2020
Up to 1 year	-	_
Over 1 year	176,725	176,725
As at December 31	176,725	176,725

There is no concentration of credit risk with respect to trade receivables, as the Company has a large number of customers, internationally dispersed.

13. OTHER RECEIVABLES

	2021	2020
Prepayments	50,830	36,813
Prepaid taxes	121,786	119,452
Other receivables	48,353	55,038
	220,969	211,303

Prepayments for VAT are refunded from the Tax authorities on regular basis.

Other non-current receivables

Non-current receivables relates to prepayments for property, plant and equipment that are due in more than 1 year.

The fair values of non-current receivables are as follows:

	2021	2020
Prepayments for property, plant and equipment	133,429	61,980
The effective interest rate on non-current receivables was as	follows:	
	2021	2020
The effective interest rate	2.00%	2.75%

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

14. CASH AND CASH EQUIVALENTS

	2021	2020
Cash balances held with banks	266,580	143,496
Cash in hand	590	907
Other	- -	18
	267,170	144,421

15. SHARE CAPITAL

_	Ordinary shares	Treasury shares	Total	
At 1 January 2020	2,220,127	(98,805)	2,121,322	
Purchase of treasury shares As at 31 December 2020	2,220,127	(10,480) (109,285)	(10,480) 2,110,842	
Purchase of treasury shares As at 31 December 2021	2,220,127	(109,285)	2,110,842	

The total authorized number of ordinary shares is 1,431,353 with a par value of EUR 25.56 per share. All issued shares are fully paid. As of 31.12.2021, the number of voting shares is 1,405,509 shares.

During 2021 no shares were acquired. During 2020, the Company acquired 800 of its own shares through Macedonian stock exchange in accordance with article 333 paragraph 1 of the Company Law. The total number of treasury shares is 22,557. The number of 3,287 treasury shares is reserved for former proprietors out of which 3,228 are priority shares and 59 are ordinary shares.

16. OTHER AND LEGAL RESERVES

		Available-for- sale	Fund for	
	Land	investments	shares	Total
At January 1, 2020	1,471,688	2,960	212,132	1,686,780
Increase	_	-	_	-
Decrease		(297)		(297)
As at December 31, 2020	1,471,688	2,663	212,132	1,686,483
Increase	-	1.753	-	1.753
Decrease	-	-	-	-
As at December 31, 2021	1,471,688	4,416	212,132	1,688,236

The nature and rights of distribution of each class of other reserves are:

- Revaluation reserves for land are created based on valuation of PP&E. These reserves are not distributable to shareholders.
- The Reserve for Available-for-sale investments is created based on valuation of investments. These reserves are not distributable to shareholders.
- Funds for shares are created from retained earnings based on the relevant decisions of the Shareholder assembly and are distributable to shareholders if not utilized.

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

16. OTHER AND LEGAL RESERVES (Continued)

	Legal reserves
At January 1, 2020	596,146
Increase	-
Decrease	-
As at December 31, 2020	596,146
Increase	-
Decrease	-
As at December 31, 2021	596,146

The company shall have a mandatory general reserve as a general reserve fund established by retaining funds from the net profit. This reserve shall be calculated and allocated as percentage determined in the company's agreement, that is, the statute and cannot be less than 5% of the profit until the reserve of the company reach an amount equal to one tenth of the basic capital. If the reserve generated in this way decreases, it has to be supplemented in the same manner.

17. BORROWINGS

Interest rates

		2021	2020
Non-current borrowings		661,083	604,335
Current borrowings		299,837	386,006
		960,920	990,341
The maturity of the borrowings is as follows:			
		2021	2020
Up to 1 year		299,837	386,006
Between 1 and 3 years		661,083	604,335
		960,920	990,341
The borrowings are denominated in following	g currencies:		
		2021	2020
EUR		-	_
MKD		960,920	990,341
		960,920	990,341
The effective interest rates at the reporting da			2020
EUR USD	MKD	December 31, EUR USD	MKD

At 31.12.2021 the Company has no defined covenanters in its bank agreements.

1.3-1.6%

1.6-1.9%

19.

20.

Stand-alone financial statements

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

18. RETIREMENT BENEFIT OBLIGATIONS

_	2021	2020
Retirement benefits	56,502	48,546
The retirement benefits are calculated based on the Company's l salaries to a vesting employee on the retirement date according to		
The amounts recognized in the Income statement are as follows	3:	
_	2021	2020
As at January 1	48,546	39,523
Increase in calculation Decrease in calculation	7,956	9,023
As at December 31	56,502	48,546
The principal actuarial assumptions used were as follows:		
	2021	2020
Discount rate	2.35%	2.32%
TRADE AND OTHER PAYABLES		
	2021	2020
Trade payables	1,594,015	1,684,684
Customer's prepayments	2,942	2,638
Payables to employees	87,255	82,334
Dividends	9,304	9,304
Deferred income from subsidies Provisions and other payables	282,810 288,947	166,219 230,899
i		2,176,078
_	2,265,273	2,170,078
PROVISION FOR OTHER LIABILITIES AND CHARGES	S	
_	2021	2020
Provision for retirement benefits	7,956	9,023
_	7,956	9,023

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

21. OTHER INCOME

	2021	2020
Collected written-off receivables	_	320
Dividends income	120,975	83,769
Interest income	539	409
Foreign exchange transaction gains	207,306	238,252
Subsidies received	60,100	30,491
Other income	67,516	56,473
	456,436	409,714
22. OTHER EXPENSES		
	2021	2020
Interest expenses	-	100
Foreign exchange transaction losses	185,217	329,561
Write-off of inventories	37,971	46,493
Other expenses	11,801	23,155
	234,989	399,309
23. EXPENSES BY NATURE		
	2021	2020
Raw materials	2,841,319	2,806,311
Cost of goods sold and raw materials	1,100,145	1,100,472
Employee benefit expenses	1,871,067	1,725,937
Depreciation and amortization	786,184	697,122
Utilities	156,820	159,942
Write off trade receivables	125.665	1,935
Transportation	125,665	191,151
Changes in the inventories	(162,272)	(224,185)
Marketing and sponsorship Maintenance expenses	895,504 87,347	810,964 78,877
Lease expenses	36,902	35,258
Insurance expenses	55,031	55,750
Temporary employment costs	76,519	105,081
Other expenses	498,423	382,298
	8,368,654	7,926,913

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

24. EMPLOYEE BENEFIT EXPENSES

	2021	2020
Gross salaries	1,568,847	1,441,173
Other employees benefits	302,220	284,764
	1,871,067	1,725,937
Number of employees at December 31	1,898	1,787

25. OPERATING LEASING

Operating leasing refers to the rental of business premises and vehicles. The usual rental period ranges from 3-5 years. The company has no option to buy the business premises and vehicles.

Expenses recorded in the Income statement are:

Minimum operating leasing	2021	2020
	36,902	35,258
	36,902	35,258
Future irrevocable liabilities	2021	2020
Up to 1 year Between 2 - 5 years	26,012 38,792	12,470 26,243
	64,804	38,713
FINANCE EXPENSES		

26.

borrowings	-	(63)
Interest expense on borrowings	(16,750)	(14,651)

27. INCOME TAX

	2021	2020
Current income tax	106,436	105,363
	106,436	105,363

2021

2020

911.70

811.00

Stand-alone financial statements

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

27. INCOME TAX (Continued)

The income tax differs from the notional amount that would arise using the tax rate applicable to profit as follows:

1,387,842	1,248,014
138,784	124,801
(2,428)	-
37,477	42,942
(67,397)	(62,380)
106,436	105,363
7.67%	8.44%
2021	2020
1,281,405,704	1,142,650,910
1,405,509	1,408,938
	138,784 (2,428) 37,477 (67,397) 106,436 7.67%

29. DIVIDENDS

The Company does not recognize the dividend payable before it is approved at the Annual General Meeting.

The dividends approved by shareholders on April 5, 2021 amounted to Denar 572,541 thousands for the year ended December 31, 2020. The approved dividends were paid and retained earnings appropriately decreased. The dividend and the tax related to the dividend are disclosed as decrease of retained earnings.

30. COMMITMENTS

Capital expenditures contracted for acquisition of property, plant and equipment at the reporting date but not yet incurred amount to Denar 163,509 thousand; (2020: Denar 51,500 thousand).

31. CONTINGENT LIABILITIES

Basic earnings per share (in Denar)

The Company has contingent liabilities with respect to the guaranties issued to third parties in the amount of Denar 60,853 thousand (2020: Denar 58,599 thousand).



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

32. RELATED PARTY TRANSACTIONS

The Company has no ultimate parent. The shares are widely held, Alkaloid AD Skopje has investments in subsidiaries stated in Note 10 above. Sales and purchases of goods and services between related parties are based on regular market terms and prices. The transactions with the related parties are stated below:

Sale of goods and services

Alkaloid DOO Belgrade, Serbia 262,038 254,179 Alkaloid INT DOO Ljubljana, Slovenia 1,200,143 1,300,636 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 282,361 281,862 Alkaloid Kons DOOEL Skopje, N. Macedonia 184,505 166,165 OOO Alkaloid RUS, Moscow, Russia 719,124 518,123 Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 Purchase of goods and services 2021 2020 Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 11,395 11,452 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Fund "Trajee Mukaetov" Skopje, N. Macedonia 10,339 10,027 <t< th=""><th><u>-</u></th><th>2021</th><th>2020</th></t<>	<u>-</u>	2021	2020
Alkaloid INT DOÖ Ljubljana, Slovenia	Alkaloid DOO Belgrade, Serbia	262.038	254 179
ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 282,361 281,862 Alkaloidpharm SA Fribourg, Switzerland 33 26 Alkaloid Kons DOOEL Skopje, N. Macedonia 184,505 166,165 OOO Alkaloid RUS, Moscow, Russia 719,124 518,123 Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 Purchase of goods and services 2021 2020 Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Japilana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,279 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid Cons DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajec Mukaetov" Skopje, N. Macedonia 10,339 10,027 OO Alka			
Alkaloidpharm SA Fribourg, Switzerland 33 26 Alkaloid Kons DOOEL Skopje, N. Macedonia 184,505 166,165 OOO Alkaloid RUS, Moscow, Russia 719,124 518,123 Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 Purchase of goods and services 2021 2020 Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Jubiljana INT, Slovenia 6,634 22,246 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid DOO Sina, Bulgaria 1,208 2,272 AlkakeKOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Bilna apteka DOOEL Skopje, N. Macedoni			
Alkaloid Kons DOOEL Skopje, N. Macedonia 184,505 166,165 OOO Alkaloid RUS, Moscow, Russia 719,124 518,123 1,121,492 1,050,067 Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,775,336 3,577,440 Purchase of goods and services 2021 2020			
OOO Alkaloid RUS, Moscow, Russia 719,124 518,123 Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 Purchase of goods and services 2021 2020 Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Soria, Bulgaria 13,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajec Mukaetov" Skopje, N. Macedonia 10,339 10,027 Alkaloid Ueledrogerija DOO Beograd, Serbia 106,345 96,790 Alkaloid HLAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 Alkaloid Kiev CO, LTD, Ukr	1 0.		
Alkaloid Veledrogerija DOO Beograd, Serbia 1,121,492 1,050,067 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 Purchase of goods and services 2021 2020 Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 13,428 12,2460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,549 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajee Mukaetov" Skopje, N. Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 OOO Alkaloid BUS, Moscow, Russia 106,345 96,790 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, U			
Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 5,640 6,382 3,775,336 3,577,440			
Purchase of goods and services 2021 2020			, ,
Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N. Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses	<u>-</u>	3,775,336	3,577,440
Alkaloid DOO Belgrade, Serbia 16,186 21,360 Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N. Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 872,102 742,913 Interest expenses 2021 2020	Purchase of goods and services		
Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 872,102 742,913 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	<u>-</u>	2021	2020
Alkaloid DOO Zagreb, Croatia 11,395 11,452 Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 872,102 742,913 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	Alkaloid DOO Belgrade, Serbia	16,186	21,360
Alkaloid DOO Ljubljana INT, Slovenia 6,634 22,460 Alkaloid DOO Sarajevo, Bosnia and Herzegovina 131,428 115,558 Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloid Kons DOOEL Skopje, N. Macedonia 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N. Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Ueledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	<u> </u>		
Alkaloid EOOD Sofia, Bulgaria 1,208 2,272 ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloidpharm SA Fribourg, Switzerland 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 872,102 742,913 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo 4,989 4,591 Alkaloidpharm SA Fribourg, Switzerland 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38		131,428	
Alkaloidpharm SA Fribourg, Switzerland 276,814 219,040 Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	Alkaloid EOOD Sofia, Bulgaria	1,208	2,272
Alkaloid Kons DOOEL Skopje, N. Macedonia 2,908 5,495 Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 872,102 742,913 Interest expenses 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo	4,989	4,591
Alkaloid DOO Podgorica, Montenegro 45,767 45,498 Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	Alkaloidpharm SA Fribourg, Switzerland	276,814	219,040
Fund "Trajce Mukaetov" Skopje, N, Macedonia 10,339 10,027 OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
OOO Alkaloid RUS, Moscow, Russia 106,345 96,790 Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
Alkaloid Veledrogerija DOO Beograd, Serbia - 922 Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
Alkaloid ILAC TLS Istanbul, Turkey 6,625 10,147 Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38		106,345	
Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia 3,007 3,036 ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 872,102 742,913 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38		-	
ALKA-LAB DOO Ljubljana, Slovenia 1,814 1,146 Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 Interest expenses 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
Alkaloid Shpk Tirana, Albania 16,942 13,630 Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 872,102 742,913 Interest expenses Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	1 10		
Alkaloid Kiev CO, LTD, Ukraine 221,635 158,406 Alkaloid LGL DOO, Zagreb 8,066 1,083 872,102 742,913 Interest expenses 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	v v		
Alkaloid LGL DOO, Zagreb 8,066 1,083 872,102 742,913 Interest expenses 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38			
Interest expenses 872,102 742,913 2021 2020 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38		· · · · · · · · · · · · · · · · · · ·	
Interest expenses 2021 Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	Alkaloid LGL DOO, Zagreb	8,066	1,083
Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	-	872,102	742,913
Alkaloid Kons DOOEL Skopje, N. Macedonia - 38	Interest expenses		
	<u>-</u>	2021	2020
	Alkaloid Kons DOOEL Skopje, N. Macedonia	<u> </u>	38
	_	<u>-</u> _	38

(In thousands of Denar)

NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

32. RELATED PARTY TRANSACTIONS (Continued)

Interest income

	2021	2020
Alkaloid Kons DOOEL Skopje, N. Macedonia	15_	
	15	

Balances and transactions between the Company and its subsidiaries arising from the sales and purchases of goods and services, advances and other transactions are presented below:

Accounts receivable	2021	2020
Alkaloid DOO Belgrade, Serbia	129,144	115,612
Alkaloid DOO Ljubljana INT, Slovenia	288,244	270,754
ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo	70,517	67,169
Alkaloidpharm SA Fribourg, Switzerland	33	-
Alkaloid Kons DOOEL Skopje, N, Macedonia	72,453	54,919
OOO Alkaloid RUS, Moscow, Russia	288,034	478,848
Alkaloid Veledrogerija DOO Beograd, Serbia	536,259	510,209
Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia	1,066	1,780
-	1,385,750	1,499,291
Accounts payable	2021	2020
Alkaloid DOO Belgrade, Serbia	2,543	950
Alkaloid DOO Zagreb, Croatia	3,529	4,887
Alkaloid DOO Ljubljana INT, Slovenia	28,308	20,653
Alkaloid DOO Sarajevo, Bosnia and Herzegovina	17,143	15,327
Alkaloid EOOD Sofia, Bulgaria	33	129
ALK&KOS Pharmaceuticals Shpk Pristine, Kosovo	3,066	932
Alkaloidpharm SA Fribourg, Switzerland	113,995	109,882
Alkaloid Kons DOOEL Skopje, N, Macedonia	-	1,182
Alkaloid DOO Podgorica, Montenegro	10,229	8,738
OOO Alkaloid RUS, Moscow, Russia	201	-
Alkaloid ILAC TLS Istanbul, Turkey	-	666
Alkaloid Bilna apteka DOOEL Skopje, N. Macedonia	929	951
ALKA-LAB DOO Ljubljana, Slovenia	1,814	1,383
Alkaloid Shpk Tirana, Albania	904	288
Alkaloid Kiev CO, LTD, Ukraine	43,038	10,947
Alkaloid LGL DOO, Zagreb	1,303	403
-	227,035	177,318
Receivables for advances and loans	2021	2020
Alkaloid Shpk Tirana, Albania	1,109	<u>-</u>
	1,109	_



NOTES TO THE STAND-ALONE FINANCIAL STATEMENTS

33. RELATED PARTY TRANSACTIONS (Continued)

Key management compensations

No compensations were paid to the Managing Board members in 2021 for the purpose of participation in the Managing board. In 2021, the amount of Denar 4,393 thousand was paid to the Supervisory Board members (2020: Denar 4,288 thousand).

33. EXCHANGE RATES OF PRINCIPAL CURRENCIES

The official exchange rate for the significant currency used in expressing the balance sheet items denominated in foreign currency is as follows:

	31-Dec-2021	31-Dec-2020	
EUR	61.63	61.69	
RUR	0.73	0.67	
USD	54.37	50.23	
CHF	59.47	56.82	

34. TAXATION RISK

The Republic of North Macedonia currently has several tax laws in effect, as imposed by the Ministry of Finance of the Republic of North Macedonia. The applicable taxes include: value added tax, corporate income tax, and personal income tax, among others. Apart from that, the regulations governing these taxes were not enforced for substantial periods of time; in contrast to similar legislation in more developed market economies. Moreover, the regulations defining the implementation of these laws are often unclear or non-existent. Hence, few precedents with regard to tax issues have been established in the Republic of North Macedonia. Often, contrary opinions pertaining to legal interpretations exist both among, and within, governmental ministries and organizations, thus creating uncertainties and areas of legal contention. Tax returns, together with all other areas regulated by the law (such as customs) are reviewed and controlled by competent authorities by several authorized vested in powers to assess severe fines and penalties.

The Company performs significant transactions with its related parties. Although the management believes that the Company possesses sufficient and adequate documentation on transfer prices, it is still uncertain whether the tax and other authorities' requirements and interpretations of the tax legislation will differ from those of the management. The management believes that any varying interpretations will have no material effects on the Company's stand-alone financial statements.

The interpretation of tax legislation by tax authorities as applied to the transactions and activity of the Company may not coincide with that of the management. As a result, transactions may be challenged by tax authorities and the Company may be assessed additional taxes, penalties and interest, which can be significant. The periods remain open to review by the tax and customs authorities with respect to tax liabilities for five years. The abovementioned explanations pose tax risks in the Republic of North Macedonia which are materially more significant than those common in the countries with more developed tax systems.

(In thousands of Denar)

35. EVENTS AFTER THE REPORTING PERIOD

On 24 February 2022, Russia engaged in military actions on Ukraine territory.

Following these events, the Company has taken necessary measures to protect its employees, and tries to provide safety conditions.

As of 31 December 2021, the Company has 100% owned subsidiary in Russia OOO Alkaloid RUS, Moscow and 100% owned TOV Alkaloid Kiev. Carrying value of investments in question as of 31 December 2021 are disclosed in the note 10 "Investments in subsidiaries".

In addition, the Company had trade receivables and sales to the third parties in the above-mentioned countries as of 31 December and for the year then ended, in the following amounts:

in MKD 000	Ukra	nine
	Trade receivables	Sales
Balance as of 12/31/2021	70,241	399,646
Subsequent collections of receivables	(70,241)	N/A
Net exposure	0	N/A

Apart from the transactions disclosed above there are no other transactions occurred with third parties in Ukraine and Russia.

As the conflict continues to evolve, it is challenging to predict the full extent and duration of its business and economic implications. Consequently, these circumstances may impact the Company with challenges relating to the investments and business operations mostly in Russia and Ukraine due to the respective governmental bodies measures and policies which have already been implemented or might be implemented in the future.

The Group management is closely monitoring developments that may impact trading activities including sanctions, actions by governments and developments in Ukraine itself. Management will further assess the impact on the investments and business operations and will take any potential actions needed, as facts and circumstances are subject to change and may be influencing trading strategies and barriers in the markets affected by the conflict. At this stage, management is not able to reliably estimate prolonged impact on the Company's future revenues and investments since the events are unfolding day-by-day.

There have been no other events that would require additional disclosures in or any adjustments to the standalone financial statements (adjusting events) until the date of their issuance.